Endologix Inc (ELGX)

5.09
0.06 1.20
NASDAQ : Health Care
Prev Close 5.03
Open 5.01
Day Low/High 5.01 / 5.45
52 Wk Low/High 6.50 / 14.89
Volume 1.86M
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 82.98M
Market Cap 393.30M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Endologix Reports Positive Clinical Data From The Ovation LUCY Study

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced 30-day results from the LUCY (Evaluation of Fema Les who are Underrepresented Candidates for Abdominal...

Endologix Provides An Update On The Nellix® Endovascular Aneurysm Sealing System U.S. Regulatory Status

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that the Company met with the Food and Drug Administration (FDA) regarding its Nellix® Endovascular...

Endologix Reports First Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2017.

Endologix, Inc. To Host An Investor Conference Call To Discuss Its Nellix® Endovascular Aneurysm Sealing System Presentation At The Society Of Vascular Surgery Annual Meeting On June 3, 2017

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr.

Endologix, Inc. To Announce First Quarter 2017 Financial Results On May 4, 2017

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the first quarter of fiscal year 2017 after the market...

Endologix Enters Into $170 Million Credit Facility With Deerfield Management

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management ("Deerfield"), a leading healthcare...

Endologix, Inc. Announces Enrollment Of First Patients In ELEVATE IDE Clinical Study

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the E xpanding Patient Applicability with Po l ymer...

Endologix Poised for a Potentially Volatile Breakout

Endologix Poised for a Potentially Volatile Breakout

The medical device maker is preparing to break out of a tight triangle pattern.

5 Stocks Trending Close to Major Breakouts

5 Stocks Trending Close to Major Breakouts

Here's how to rake in some potentially big profits off a number of breakout setups.

Endologix, Inc. To Present At The Oppenheimer 27th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chairman and Chief Executive Officer, will present at the Oppenheimer 27 th...

DEADLINE ALERT: Brower Piven Reminds Investors Of The March 6, 2017 Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess Of $100,000 From Investment In Endologix Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

5 Stocks Set for Explosive Breakouts

5 Stocks Set for Explosive Breakouts

Here's how to rake in the profits off some potential big breakouts.

Commit To Purchase Endologix At $5, Earn 22.8% Annualized Using Options

Investors considering a purchase of Endologix Inc. shares, but cautious about paying the going market price of $6.46/share, might benefit from considering selling puts among the alternative strategies at their disposal.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Endologix, Inc. Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 6, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Endologix, Inc.

ELGX: Insiders vs. Shorts

The most recent short interest data was recently released for the 01/31/2017 settlement date, and Endologix Inc. is one of the most shorted stocks of the Russell 3000, based on 9.97 "days to cover" versus the median component at 5.13.

EGLX SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Endologix, Inc. And A Lead Plaintiff Deadline Of March 6, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Endologix, Inc.

Endologix Completes Patient Enrollment In The Ovation® LUCY Study

First Prospective Study Evaluating EVAR in a Female Population

Endologix Stock Sees Short Interest Jump 24%

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 3,891,942 share increase in total short interest for Endologix Inc. , to 20,115,723, an increase of 23.99% since 01/13/2017.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Endologix, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of March 6, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Endologix, Inc.